Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-transfected dendritic cell vaccination in high-risk uveal melanoma
2008-001974-33Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2008
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mRNA-electroporated dendritic cell product in intraocular melanoma, sponsored by Radboud University Medical Center. Primary endpoint: Progression-free survival. Started Sep 2008; status: completed.
02
Drugs
mRNA-electroporated dendritic cell product
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on 2008-001974-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001974-33.